Anemia in Adults With Congenital Heart Disease Relates to Adverse Outcome

Journal of the American College of Cardiology

Volumn 54, Issue 22, 2009, Pages 2093-2100

  Dimopoulos, Konstantinos ^a,b   Diller, Gerhard Paul ^a,b   Giannakoulas, Georgios ^a   Petraco, Ricardo ^a   Chamaidi, Aikaterini ^a   Karaoli, Evaggelia ^a   Mullen, Michael ^a   Swan, Lorna ^a   Piepoli, Massimo F ^b   Poole Wilson, Philip A ^b   Francis, Darrel P ^c   Gatzoulis, Michael A ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c ST MARY S HOSPITAL   (United Kingdom)

Author keywords

anemia; congenital heart defects; prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN; WARFARIN;

ADULT; ANEMIA; ARTICLE; CONGENITAL HEART DISEASE; CREATININE BLOOD LEVEL; DEATH; DISEASE ASSOCIATION; FEMALE; FUNCTIONAL STATUS; GREAT VESSELS TRANSPOSITION; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TRICUSPID VALVE ATRESIA;

ADOLESCENT; ADULT; ANEMIA; EBSTEIN ANOMALY; FEMALE; HEART DEFECTS, CONGENITAL; HEMOGLOBINS; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; RISK ASSESSMENT; TRANSPOSITION OF GREAT VESSELS; YOUNG ADULT;

EID: 71849083465     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.06.050     Document Type: Article

References (44)

1. Al-Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962
2. Go A.S., Yang J., Ackerson L.M., et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 113 (2006) 2713-2723
3. Sharma R., Francis D.P., Pitt B., Poole-Wilson P.A., Coats A.J.S., and Anker S.D. Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 25 (2004) 1021-1028
4. Anand I., McMurray J.J.V., Whitmore J., et al. Anemia and its relationship to clinical outcome in heart failure. Circulation 110 (2004) 149-154
5. Anand I.S. Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med 6 Suppl 3 (2005) S13-S21
6. Kosiborod M., Smith G.L., Radford M.J., Foody J.M., and Krumholz H.M. The prognostic importance of anemia in patients with heart failure. Am J Med 114 (2003) 112-119
7. McClellan W.M., Flanders W.D., Langston R.D., Jurkovitz C., and Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 13 (2002) 1928-1936
8. Szachniewicz J., Petruk-Kowalczyk J., Majda J., et al. Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol 90 (2003) 303-308
9. Valeur N., Nielsen O.W., McMurray J.J., Torp-Pedersen C., and Kober L. Anaemia is an independent predictor of mortality in patients with left ventricular systolic dysfunction following acute myocardial infarction. Eur J Heart Fail 8 (2006) 577-584
10. Tang Y.-D., and Katz S.D. Anemia in chronic heart failure: prevalence, etiology, clinical correlates, and treatment options. Circulation 113 (2006) 2454-2461
11. Kosiborod M., Curtis J.P., Wang Y., et al. Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med 165 (2005) 2237-2244
12. O'Meara E., Clayton T., McEntegart M.B., et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 113 (2006) 986-994
13. Kazory A., and Ross E.A. Anemia: The point of convergence or divergence for kidney disease and heart failure?. J Am Coll Cardiol 53 (2009) 639-647
14. Bolger A.P., Sharma R., Li W., et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106 (2002) 92-99
15. Ohuchi H., Takasugi H., Ohashi H., et al. Abnormalities of neurohormonal and cardiac autonomic nervous activities relate poorly to functional status in Fontan patients. Circulation 110 (2004) 2601-2608
16. Davos C.H., Davlouros P.A., Wensel R., et al. Global impairment of cardiac autonomic nervous activity late after repair of tetralogy of Fallot. Circulation 106 (2002) I69-I75
17. Davos C.H., Francis D.P., Leenarts M.F., et al. Global impairment of cardiac autonomic nervous activity late after the Fontan operation. Circulation 108 Suppl 1 (2003) II180-II185
18. Dimopoulos K., Diller G.P., Koltsida E., et al. Prevalence, predictors, and prognostic value of renal dysfunction in adults with congenital heart disease. Circulation 117 (2008) 2320-2328
19. Collins N., Piran S., Harrison J., Azevedo E., Oechslin E., and Silversides C.K. Prevalence and determinants of anemia in adults with complex congenital heart disease and ventricular dysfunction (subaortic right ventricle and single ventricle physiology). Am J Cardiol 102 (2008) 625-628
20. Nutritional anaemias. Report of a WHO scientific group. World Health Organ Tech Rep Ser 405 (1968) 5-37
21. Dimopoulos K., Okonko D.O., Diller G.P., et al. Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival. Circulation 113 (2006) 2796-2802
22. R Development Core Team. R: A language and environment for statistical computing (2008), R Foundation for Statistical Computing, Vienna, Austria
23. Rubin D.B. Multiple Imputation for Nonresponse in Surveys (1987), Wiley, New York, NY
24. Broberg C.S., Bax B.E., Okonko D.O., et al. Blood viscosity and its relationship to iron deficiency, symptoms, and exercise capacity in adults with cyanotic congenital heart disease. J Am Coll Cardiol 48 (2006) 356-365
25. Deswal A., Petersen N.J., Feldman A.M., Young J.B., White B.G., and Mann D.L. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 103 (2001) 2055-2059
26. Macdougall I.C., and Cooper A.C. Erythropoietin resistance: the role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant 17 Suppl 11 (2002) 39-43
27. Weiss G., and Goodnough L.T. Anemia of chronic disease. N Engl J Med 352 (2005) 1011-1023
28. Macdougall I.C., and Cooper A.C. Hyporesponsiveness to erythropoietic therapy due to chronic inflammation. Eur J Clin Invest 35 Suppl 3 (2005) 32-35
29. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102 (2003) 783-788
30. Nemeth E., Tuttle M.S., Powelson J., et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306 (2004) 2090-2093
31. Hasper D., Hummel M., Kleber F.X., Reindl I., and Volk H.D. Systemic inflammation in patients with heart failure. Eur Heart J 19 (1998) 761-765
32. Sharma R., Bolger A.P., Li W., et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol 92 (2003) 188-193
33. Niebauer J., Volk H.D., Kemp M., et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 353 (1999) 1838-1842
34. Dimopoulos K., Diller G.P., Piepoli M.F., and Gatzoulis M.A. Exercise intolerance in adults with congenital heart disease. Cardiol Clin 24 (2006) 641-660
35. Diller G.P., Dimopoulos K., Okonko D., et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 112 (2005) 828-835
36. Raphael C., Briscoe C., Davies J., et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure. Heart 93 (2007) 476-482
37. Go A.S., Chertow G.M., Fan D., McCulloch C.E., and Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351 (2004) 1296-1305
38. Silverberg D.S., Wexler D., Blum M., et al. Effects of treatment with epoetin Beta on outcomes in patients with anaemia and chronic heart failure. Kidney Blood Press Res 28 (2005) 41-47
39. Silverberg D.S., Wexler D., Blum M., et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35 (2000) 1737-1744
40. Silverberg D.S., Wexler D., Sheps D., et al. The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 37 (2001) 1775-1780
41. Perloff J.K., Rosove M.H., Child J.S., and Wright G.B. Adults with cyanotic congenital heart disease: hematologic management. Ann Intern Med 109 (1988) 406-413
42. Rosove M.H., Perloff J.K., Hocking W.G., Child J.S., Canobbio M.M., and Skorton D.J. Chronic hypoxaemia and decompensated erythrocytosis in cyanotic congenital heart disease. Lancet 2 (1986) 313-315
43. Oechslin E. Hematological management of the cyanotic adult with congenital heart disease. Int J Cardiol 97 Suppl 1 (2004) 109-115
44. Spence M.S., Balaratnam M.S., and Gatzoulis M.A. Clinical update: cyanotic adult congenital heart disease. Lancet 370 (2007) 1530-1532